A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.J Alzheimers Dis. 2010; 21(3):903-14.JA
Abstract
There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process.
Links
MeSH
Pub Type(s)
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Language
eng
PubMed ID
20693639
Citation
Quinn, Joseph F., et al. "A Copper-lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 21, no. 3, 2010, pp. 903-14.
Quinn JF, Harris CJ, Cobb KE, et al. A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2010;21(3):903-14.
Quinn, J. F., Harris, C. J., Cobb, K. E., Domes, C., Ralle, M., Brewer, G., & Wadsworth, T. L. (2010). A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 21(3), 903-14. https://doi.org/10.3233/JAD-2010-100408
Quinn JF, et al. A Copper-lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2010;21(3):903-14. PubMed PMID: 20693639.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
AU - Quinn,Joseph F,
AU - Harris,Christopher J,
AU - Cobb,Katherine E,
AU - Domes,Christopher,
AU - Ralle,Martina,
AU - Brewer,George,
AU - Wadsworth,Teri L,
PY - 2010/8/10/entrez
PY - 2010/8/10/pubmed
PY - 2011/1/19/medline
SP - 903
EP - 14
JF - Journal of Alzheimer's disease : JAD
JO - J Alzheimers Dis
VL - 21
IS - 3
N2 - There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process.
SN - 1875-8908
UR - https://www.unboundmedicine.com/medline/citation/20693639/A_copper_lowering_strategy_attenuates_amyloid_pathology_in_a_transgenic_mouse_model_of_Alzheimer's_disease_
L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-2010-100408
DB - PRIME
DP - Unbound Medicine
ER -